ArticleMacromolecular bioscience2026
Recombinant Antifreeze Protein Type I as a Potential Peptide-Based Anti-Fouling Material for Biomedical Surfaces.
Article in Macromolecular bioscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Anti-fouling of material surfaces is a major concern in the performance of biomedical materials in biological environments. Surface modification of polymeric materials is an effective strategy for controlling the anti-fouling properties of biomedical materials. Synthetic polymers such as poly(ethylene glycol) (PEG), which exhibit high bioinertness and anti-fouling properties, are widely used. Peptide-based anti-fouling materials are gaining attention because of their biocompatibility, long-term biodegradability, and structural diversity. In this study, we explored the potential of antifreeze protein type I (AFP) from winter flounder as a peptide-based anti-fouling material. AFP possesses a simple α-helical structure of approximately 30 amino acid residues and presents an amphiphilic interface consisting of an ice-binding surface and a hydrophilic surface. We constructed a recombinant AFP that can be modified on a glass substrate and evaluated its anti-fouling properties. The AFP-modified substrates significantly suppressed the adsorption of plasma proteins, such as human albumin, fibrinogen, and fibronectin. Furthermore, adhesion of human ovarian cancer SKOV3 cells and mouse platelets to the substrates was suppressed by AFP modification. Notably, tandem-repeat AFP constructs exhibited high resistance to proteolytic enzymes, such as trypsin. These findings highlight the potential of recombinant AFP as a potential peptide-based anti-fouling material for biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.